Superpowerful small wind turbines light up the night
[Thanks, Yocheved]
AMD's managed to distract us a bit from its troubles lately with some interesting chip announcements and bold predictions, but reality keeps setting in -- the company announced another executive shuffling today as the company keeps losing money and ground to Intel. Out this time are former EVP of Computing Solutions Mario Rivas and "Chief Talent Officer" Michel Cadieux, as well as 1600 workers being laid off worldwide. Former server chief Randy Allen will replace Rivas and Allen Sockwell is getting Cadieux's old job, but the more interesting move is the creation of a new division called Central Engineering, which will oversee all of the company's roadmaps from here on out. Hopefully that means we'll see fewer incomprehensible roadmap updates and more shipping chips -- that's the only way things are going to improve in Sunnyvale.
We're not usually too down with enterprise-services action, but it's hard not to notice HP's $12-13B bid to buy out rival Electronic Data Systems. EDS is best remembered for that "Herding Cats" Super Bowl commercial, but things have been rough lately -- the company just posted 62 percent decline in first-quarter profits. Still, EDS remains a leader in technology outsourcing, and HP seems to think that it'll be better able to take down Big Blue's powerhouse services and consulting group if they merge. The deal isn't done yet, but we should know how things go soon.
We may already have spray-on bandages, but Arch Therapeutics has developed a nanostructured substance that they say stops bleeding almost instantly. Originally developed at MIT, the material is awaiting FDA approval and could make its way into operating rooms soon. The liquid is made up of amino acids that form peptides and cluster into long fibers when exposed to salty environments, like, say, a whole bunch of blood. The material isn't terribly new -- it was originally discovered in the 90s, but only recently during an experiment did researchers realize that it would be great for blood control. Shortly thereafter, people saw dollar signs and Arch Therapeutics was founded.
There weren't a whole lot of firm details on the reasons behind Apple's acquisition of chip designer P.A. Semi to be had back when the deal was announced last month, but it seems that a bit of the veil of mystery may now be lifting, at least if the word EETimes is hearing from its unnamed source is to be believed. Apparently, Apple was keen to have P.A. Semi's crack chip-making team design a new chip for them, but P.A. Semi had "more or less burnt through its venture capital funds," leaving them unable to take on the project. According to EETimes source, that meant that the only way to get P.A. Semi involved was for Apple to pay off all of P.A.'s investors and bring the company in-house, something they were able to do for a mere $280 million or so. Of course, as EETimes points out, the big question remaining is exactly what it is that Apple wants P.A. Semi to help it out with, and that's a detail we'd expect to take considerably longer to trickle out.








Other Weblogs Inc. Network blogs you might be interested in: